A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents NEOGENOMICS, INC. PART I NeoGenomics, Inc., a Nevada corporation (referred to individually as the “Company” or collectively with its subsidiaries as “NeoGenomics,” “we,” “us,” or “our” in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “NEO.” NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology. We operate a network of cancer-focused testing laboratories in the United States and the United Kingdom. Our mission is to save lives by improving patient care. Our vision is to become the world’s leader in cancer testing, information, and decision support by providing uncompromising quality, exceptional service, and innovative solutions.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 727M | 727M | 661M | 592M | 510M | 484M |
| Net Income | -108M | -108M | -79M | -88M | -144M | -8.3M |
| EPS | $-0.84 | $-0.84 | $-0.62 | $-0.70 | $-1.16 | $-0.07 |
| Free Cash Flow | -22M | -22M | -34M | -31M | -97M | -91M |
| ROIC | -8.4% | -8.9% | -6.3% | -5.9% | -9.4% | -0.5% |
| Gross Margin | 43.2% | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% |
| Debt/Equity | 0.49 | 0.49 | 0.89 | 0.65 | 0.61 | 0.55 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -116M | -116M | -92M | -108M | -158M | -119M |
| Operating Margin | -15.9% | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% |
| ROE | -12.9% | -12.4% | -8.7% | -9.3% | -14.5% | -0.8% |
| Shares Outstanding | 129M | 129M | 127M | 126M | 124M | 119M |
NEOGENOMICS INC passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 40.8%. At current prices, the estimated annualized return to fair value is -7.6%.
NEOGENOMICS INC (NEO) has a 5-year average return on invested capital (ROIC) of -6.2%. This is below average and may indicate limited pricing power.
NEOGENOMICS INC (NEO) has a market capitalization of $1.1B. It is classified as a small-cap stock.
NEOGENOMICS INC (NEO) does not currently pay a regular dividend.
NEOGENOMICS INC (NEO) operates in the Services-Testing Laboratories industry, within the Industrials sector.
NEOGENOMICS INC (NEO) reported annual revenue of $727 million in its most recent fiscal year, based on SEC EDGAR filings.
NEOGENOMICS INC (NEO) has a net profit margin of -14.9%. The company is currently unprofitable.
NEOGENOMICS INC (NEO) generated $-22 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NEOGENOMICS INC (NEO) has a debt-to-equity ratio of 0.49. This indicates a conservatively financed balance sheet.
NEOGENOMICS INC (NEO) reported earnings per share (EPS) of $-0.84 in its most recent fiscal year.
NEOGENOMICS INC (NEO) has a return on equity (ROE) of -12.4%. A negative ROE may indicate losses or negative equity.
NEOGENOMICS INC (NEO) has a 5-year average gross margin of 40.8%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for NEOGENOMICS INC (NEO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NEOGENOMICS INC (NEO) has a book value per share of $6.51, based on its most recent annual SEC filing.